Patients undergoing complex gastrointestinal malignancy surgeries experience various challenges such as immune system ...

Research on using sedation to improve patient tolerance to noninvasive ventilation (NIV) after traumatic chest injuries is ...

Objectives: Although generally effective for sedation during noninvasive procedures, dexmedetomidine as the sole agent has not been uniformly successful for invasive procedures. To overcome some ...

The case reports described in this review article demonstrate the benefit that patients have derived from the adjunctive use of dexmedetomidine to their current treatment regimen for alcohol ...

BioXcel Therapeutics (BTAI) stock gains as company shifts focus from commercial support for FDA-approved drug, Igalmi to lead ...

Recently initiated SERENITY At-Home pivotal Phase 3 trial for agitation associated with bipolar disorders or schizophrenia ...

BioXcel Therapeutics has announced a clinical reprioritization, focusing on late-stage development of its agitation treatment ...

A recent study on the effects of commonly used anaesthetic and sedative drugs on cerebrospinal fluid flow and volume has uncovered significant findings regarding their impact on the brain's vital ...

Dexmedetomidine hydrochloride 1 is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Pain. According to GlobalData, Phase III drugs for Pain have a 54% phase ...

Perhaps we haven’t been really up to date with our drug practice. [ICU1] Below, the clinicians commented on the new agent dexmedetomidine, which has recently been introduced. SeniorNurse1: It is ...

The PCIA pump was attached to all the patients after surgery. It was mainly filled with 2.0–2.5 µg/kg of sufentanil or 8–10 mg of butorphanol with 1–1.5 µg/kg of dexmedetomidine and 10 mg of ...